Inhibition of in vitro angiogenesis by 2-methoxy- and 2-ethyl-estrogen sulfamates

International Journal of Cancer

Volumn 109, Issue 4, 2004, Pages 533-540

  Newman, Simon P ^a   Leese, Mathew P ^b   Purohit, Atul ^a   James, David R C ^a   Rennie, Catherine E ^a   Potter, Barry V L ^b   Reed, Michael J ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b University of Bath   (United Kingdom)

Author keywords

Angiogenesis; Breast cancer; Estrogen sulfamates; Estrogens; Microtubules

Indexed keywords

2 ETHYLESTRADIOL; 2 ETHYLESTRADIOL 3 O SULFAMATE; 2 ETHYLESTROGEN SULFAMATE DERIVATIVE; 2 ETHYLESTRONE; 2 ETHYLESTRONE 3 O SULFAMATE; 2 METHOXYESTRADIOL; 2 METHOXYESTRADIOL 3 O SULFAMATE; 2 METHOXYESTRADIOL 3,17 O,O BISSULFAMATE; 2 METHOXYESTROGEN SULFAMATE DERIVATIVE; 2 METHOXYESTRONE; 2 METHOXYESTRONE 3 O SULFAMATE; ANGIOGENESIS INHIBITOR; ESTROGEN DERIVATIVE; PROTEIN BCL 2; PROTEIN P53; SULFONAMIDE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA MICROARRAY; DRUG MECHANISM; DRUG POTENCY; ENDOTHELIUM CELL; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MICROTUBULE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UMBILICAL VEIN;

ANGIOGENESIS INHIBITORS; APOPTOSIS; CELL MOVEMENT; CELLS, CULTURED; COCULTURE TECHNIQUES; ENDOTHELIAL CELLS; ESTRADIOL; FIBROBLASTS; GENE EXPRESSION PROFILING; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; SKIN; SULFONIC ACIDS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 1542510122     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20045     Document Type: Article

References (35)

1. Martucci C, Fishman J. Direction of estradiol metabolism as a control of its hormonal action: uterotropic activity of estradiol metabolites. Endocrinology 1977;101:1709-15.
2. Martucci C, Fishman J. Impact of continuously administered catechol estrogens on uterine growth and luteinizing hormone secretion. Endocrinology 1979;105:1288-92.
3. Bradlow HL, Telang NT, Sepkovic DW, Osborne MP. 2-Hydroxyestrone: the 'good' estrogen. J Endocrinol 1996;150:5259-65.
4. Swaneck GE, Fishman J. Covalent binding of endogenous 16α-hydroxyestrone to estradiol receptor in human breast cancer cells: characterisation and intra nuclear location. Proc Natl Acad Sci USA 1988;85:7831-5.
5. Zhu BT, Conney AH. Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res 1998; 58:2269-77.
6. Brem S. Angiogenesis antagonists: current clinical trials. Angiogenesis 1998;2:9-20.
7. Seegers JC, Avelin M-L, Van Aswegen CH, Cross M, Koch F, Joubert WS. The cytotoxic effects of estradiol-17β, catecholestradiols and methoxyestradiols on dividing MCF-7 and HeLa cells. J Steroid Biochem 1989;32:797-809.
8. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and Taxol. Cancer Res 1997;57:81-6.
9. Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, Schweigerer L. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994;368:237-9.
10. Reiser F, Way D, Bernas M, Witte M, Witte C. Inhibition of normal and experimental angio tumor endothelial cell proliferation and cell cycle progression by 2-methoxyestradiol. Proc Soc Exp Biol Med 1998;219:211-6.
11. Howarth NM, Purohit A, Reed MJ, Potter BVL. Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential. J Med Chem 1994;37:219-21.
12. Purohit A, Williams GJ, Howarth NM, Potter BVL, Reed MJ. Inactivation of steroid sulfatase by an active site-directed inhibitor, estrone-3-O-sulfamate. Biochemistry 1995;34:11508-14.
13. Elger W, Schwarz S, Hedden A, Reddersen G, Schneider B. Sulfamates of various estrogens as prodrugs with increased systemic and reduced hepatic estrogenicity at oral application. J Steroid Biochem Mol Biochem 1995;55:395-403.
14. Elger W, Palme H-J, Schwarz S. Novel oestrogen sulfamates: a new approach to oral hormone therapy. Exp Opin Invest Drugs 1998;7: 575-89.
15. Purohit A, Vernon KA, Wagenaar-Humelinck AE, Woo LWL, Hejaz HAM, Potter BVL, Reed MJ. The development of A-ring modified analogues of oestrone-3-O-sulphamate as steroid sulphatase inhibitors with reduced oestrogenicity. J Steroid Biochem Mol Biol 1998;64: 269-75.
16. MacCarthy-Morrogh L, Townsend PA, Purohit A, Potter BVL, Reed MJ, Packham G. Differential effects of estrone and estrone-3-O-sulfamate derivatives on mitotic arrest, apoptosis and microtubule assembly in human breast cancer cells. Cancer Res 2000;60:5441-50.
17. Purohit A, Hejaz HAM, Walden L, MacCarthy-Morrogh L, Packham G, Potter BVL, Reed MJ. The effect of 2-methoxyoestrone-3-O-sulphamate on the growth of breast cancer cells and induced mammary tumours. Int J Cancer 2000;85:584-9.
18. Okada M, Iwashita S, Koizumi N. Efficient and general method for sulfamoylation of a hydroxyl group. Tetrahedron Lett 2000;41:7047-51.
19. Bishop ET, Bell GT, Bloor S, Broom IJ, Hendry NFK, Wheatley DN. An in vitro model of angiogenesis: basic factors. Angiogenesis 1999; 3:335-44.
20. Purohit A, Woo LWL, Chander SK, Newman SP, Ho Y, Grasso A, Leese MP, Potter BVL, Reed MJ. Steroid sulphatase inhibitors for breast cancer therapy. J Steroid Biochem Mol Biol 2003;86:423-32.
21. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med 1995;1:27-31.
22. Weidener N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995;147:9-19.
23. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
24. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis of tumor growth. Cell 1997;88:277-85.
25. Pribluda VS, Gubish ER, LaVallee TM, Treston A, Swartz GM, Green SJ. 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Met Rev 2000;19:173-9.
26. Donovan D, Brown NJ, bishop ET, Lewis CE. Comparison of three in vitro human 'angiogenesis' assays with capillaries formed in vivo. Angiogenesis 2001;4:113-21.
27. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003;3:363-75.
28. D'Amato RJ, Lin CM, Flynn E, Folkman J, Hamel E. 2-Methoxyestradiol, and endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci USA 1994;91:3964-8.
29. Poruchynsky MS, Wang EE, Rudin CM, Blagosklonny MV, Fojo T. Bcl-xL is phosphorylated in malignant cancer cells following microtuble disruption. Cancer Res 1998;58:3331-8.
30. Attalla H, Westberg JA, Andersson LC, Adlercreutz H, Makela TP. 2-Methoxyestradiol-induced phosphorylation of Bcl-2: uncoupling from JNK/SAPK activation. Biochem Biophys Res Comm 1998;247: 616-9.
31. Huang Y, Ray S, Reed JC, Ibrado AM, Tang C, Nawabi A, Bhalla K. Estrogen increases intracellular p26 Bcl-2 to p21 Bax ratios and inhibits Taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Res Treat 1997;42:73-81.
32. Purohit A, Singh A, Ghilchik MW, Reed MJ. Inhibition of tumour necrosis factor α-stimulated aromatase activity by microtuble-stabilizing agents, paclitaxel and 2-methoxyestradiol. Biochem Biophys Res Comm 1999;261:214-7.
33. Reed MJ, Purohit A. Breast cancer and the role of cytokines in regulating estrogen synthesis: an emerging hypothesis. Endocrine Rev 1997;18:701-15.
34. Madge L, Sierra-Honigmann MR, Pobert JS. Apoptosis-inducing agents cause rapid shedding of tumor necrosis factor receptor 1. J Biol Chem 1999;274:13643-9.
35. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-64.